Skip to main content

Table 1 Baseline clinical characteristics of patients receiving high dose chemoradiotherapy

From: High dose chemoradiotherapy increases chance of organ preservation with satisfactory functional outcome for rectal cancer

Variable N = 57
Age at diagnosis, n (%)  
 Median, y (range) 59 (29–84)
  < 60y 30 (52.6)
  ≥ 60y 27 (47.4)
Sex, n (%)  
 Male 44 (77.2)
 Female 13 (22.8)
Baseline CEA (mg/mL)  
 < 5.00 mg/mL 35 (61.4)
 ≥ 5.00 mg/mL 22 (38.6)
T stage, n (%)  
 T1 1 (1.8)
 T2 10 (17.5)
 T3 33 (57.9)
 T4 13 (22.8)
N stage, n (%)  
 N0 21 (36.8)
 N1 23 (40.4)
 N2 13 (22.8)
AJCC/UICC stage, n (%)  
 Stage I 5 (8.8)
 Stage II 16 (28.1)
 Stage III 36 (63.2)
Histopathology (differentiation), n (%)  
 Poorly differentiated 8 (14.0)
 Moderately differentiated 33 (57.9)
 Undefined 16 (28.1)
Distance to the anal verge, n (%)  
 Median, cm (range) 3.0 (0.0–10.0)
  ≤ 5.0 cm 53 (93.0)
  > 5.0 cm 4 (7.0)
Length, n (%)  
 Median, cm (range) 5.0 (2.0–11.0)
  < 5.0 cm 28 (49.1)
  ≥ 5.0 cm 29 (50.9)
Adjacent organ invasion, n (%)  
 Yes 9 (15.8)
 No 48 (84.2)
Comorbidities, n (%)  
 Yes 10 (17.5)
 No 47 (82.5)
  1. CEA carcinoembryonic antigen, AJCC/UICC American Joint Committee on Cancer/International Union Against Cancer